BRPI0509553A - derivados de nucleosìdeo e uso terapêutico dos mesmos - Google Patents

derivados de nucleosìdeo e uso terapêutico dos mesmos

Info

Publication number
BRPI0509553A
BRPI0509553A BRPI0509553-0A BRPI0509553A BRPI0509553A BR PI0509553 A BRPI0509553 A BR PI0509553A BR PI0509553 A BRPI0509553 A BR PI0509553A BR PI0509553 A BRPI0509553 A BR PI0509553A
Authority
BR
Brazil
Prior art keywords
nucleoside derivatives
therapeutic use
compounds
nucleoside
administering
Prior art date
Application number
BRPI0509553-0A
Other languages
English (en)
Inventor
Chang H Ahn
Won J Choi
Young B Lee
Lak S Jeong
Sang K Lee
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Publication of BRPI0509553A publication Critical patent/BRPI0509553A/pt
Publication of BRPI0509553B1 publication Critical patent/BRPI0509553B1/pt
Publication of BRPI0509553B8 publication Critical patent/BRPI0509553B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

DERIVADOS DE NUCLEOSìDEO E USO TERAPêUTICO DOS MESMOS. A presente invenção refere-se a derivados de nucleosídeo representados por fórmulas gerais I e II, a seus processos sintéticos e aos sais farmacologicamente aceitáveis dos mesmos e a composições que contêm tais compostos. Também estão incluídos processos para o tratamento de distúrbios hiperproliferativos por administração dos compostos.
BRPI0509553A 2004-04-01 2005-04-01 derivados de nucleosídeos, seu processo de síntese e uso terapêutico dos mesmos BRPI0509553B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55814104P 2004-04-01 2004-04-01
US60/558,141 2004-04-01
PCT/US2005/011313 WO2005097757A2 (en) 2004-04-01 2005-04-01 Nucleoside derivatives and therapeutic use thereof

Publications (3)

Publication Number Publication Date
BRPI0509553A true BRPI0509553A (pt) 2007-09-18
BRPI0509553B1 BRPI0509553B1 (pt) 2019-06-18
BRPI0509553B8 BRPI0509553B8 (pt) 2021-05-25

Family

ID=34979006

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509553A BRPI0509553B8 (pt) 2004-04-01 2005-04-01 derivados de nucleosídeos, seu processo de síntese e uso terapêutico dos mesmos

Country Status (15)

Country Link
US (1) US7405214B2 (pt)
EP (1) EP1732902B1 (pt)
JP (2) JP5001832B2 (pt)
KR (1) KR100926596B1 (pt)
CN (2) CN102091072A (pt)
AT (1) ATE453628T1 (pt)
AU (1) AU2005230676B2 (pt)
BR (1) BRPI0509553B8 (pt)
CA (1) CA2562965C (pt)
DE (1) DE602005018620D1 (pt)
ES (1) ES2334803T3 (pt)
IN (1) IN2014DN04587A (pt)
MX (1) MXPA06011141A (pt)
PL (1) PL1732902T3 (pt)
WO (1) WO2005097757A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315534B2 (en) * 2007-08-10 2016-04-19 Board Of Regents Of The University Of Nebraska Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents
CA2785395A1 (en) * 2009-12-23 2011-06-30 Board Of Regents Of The University Of Nebraska Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
CN110483413B (zh) 2013-03-15 2023-02-28 百缮药业(苏州)有限公司 用于制备碳环糖衍生物的方法
CN107750160B (zh) 2015-06-09 2021-06-22 百缮药业(苏州)有限公司 氟代环戊烯基胞嘧啶的用途及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6187674A (ja) * 1984-10-06 1986-05-06 Yoshitomi Pharmaceut Ind Ltd シクロペンテン環を有する新規ヌクレオシド
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
CN1646141B (zh) * 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
TWI299664B (en) * 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds

Also Published As

Publication number Publication date
EP1732902A2 (en) 2006-12-20
CA2562965C (en) 2013-10-29
BRPI0509553B1 (pt) 2019-06-18
JP2007531736A (ja) 2007-11-08
KR20070012685A (ko) 2007-01-26
ATE453628T1 (de) 2010-01-15
CA2562965A1 (en) 2005-10-20
PL1732902T3 (pl) 2010-06-30
KR100926596B1 (ko) 2009-11-11
CN1980898B (zh) 2011-01-12
US7405214B2 (en) 2008-07-29
CN102091072A (zh) 2011-06-15
JP5001832B2 (ja) 2012-08-15
AU2005230676A1 (en) 2005-10-20
IN2014DN04587A (pt) 2015-07-10
BRPI0509553B8 (pt) 2021-05-25
JP2012107072A (ja) 2012-06-07
EP1732902B1 (en) 2009-12-30
MXPA06011141A (es) 2007-08-14
DE602005018620D1 (de) 2010-02-11
AU2005230676B2 (en) 2010-10-07
US20050222185A1 (en) 2005-10-06
CN1980898A (zh) 2007-06-13
WO2005097757A2 (en) 2005-10-20
ES2334803T3 (es) 2010-03-16
WO2005097757A3 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BRPI0513717A (pt) derivados de piridina
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BRPI0606793A8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
BRPI0508085A (pt) compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0606437A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
BRPI0511999A (pt) compostos como antagonistas de ccr5
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF